Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Spiro Rombotis

President and Chief Executive Officer

Cyclacel Pharmaceuticals, Inc.

President and CEO, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC; CYCCP), a late-stage, cancer drug development company based in Scotland and New Jersey, since 1996 when it began operations. Over 34 years, at three publicly-held biotechs and two pharmas, participated in several drug programs that reached the market, mainly in inflammation and hematology/oncology. Previously a Vice President and Managing Director, Europe at Liposome (subsequently acquired by Elan) and a Vice President at Bristol-Myers Squibb, he began his career in the early ’80s, after training at Novartis, as one of the first employees of Centocor (a pioneering biopharmaceutical company subsequently acquired by Johnson & Johnson). MBA and MPH with honors, Kellogg School of Management, Northwestern University and BA, Williams College. Serves on the Board of Trustees of BioNJ, the NJ biotech association.

This speaker's sessions:

Back